Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Phase III Results Show Vabysmo Improved Vision in Japanese Patients
Details : Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, which is being evaluated for angioid streaks associated with neovascularization.
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vabysmo (faricimab-svoa) is the first bispecific antibody approved for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial gr...
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2023
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Santen EMA Filing for STN1013001 Cationic Emulsion in Glaucoma Treatment
Details : STN1013001 is a preservative-free latanoprost eye drop cationic emulsion, a prostaglandin F2α analogue, which is a selective proteinoid FP receptor agonist being developed for Open-Angle Glaucoma.
Product Name : Catiolanze
Product Type : HPAPI
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Faricimab is the first investigational bispecific antibody designed for the eye) It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions.
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
November 06, 2021
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Santen Announces U.S. FDA Filing Acceptance of NDA for Cyclosporine Topical Ophthalmic Emulsion
Details : Cyclosporine topical ophthalmic emulsion, 0.1% is an investigational treatment for severe VKC in patients ages 4-18. U.S. Food and Drug Administration (FDA) has accepted its NDA submission which is supported by robust data from VEKTIS trial.
Product Name : Verkazia
Product Type : Peptide
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
7-day Levofloxacin/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery
Details : The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye drops were as effective as 14-day tobramycin/dexamethasone eye drops to treat ocular inflammation and prevent infection in post-cataract surgery patients.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable